Moderna stock jumps 120% after the US drugmaker and Merck reported positive results from a late-stage trial of their personalised mRNA cancer vaccine.
The news sent Moderna shares sharply higher as investors reacted to the potential of a new approach to treating melanoma.
The experimental vaccine, intismeran, is being developed by Moderna in partnership with Merck.
It is designed to work alongside Merck’s cancer immunotherapy Keytruda and is being tested in patients with melanoma whose tumours had been surgically removed.
Moderna Stock Jumps 120% On Trial Results
The companies said the Phase 3 study met its key goals, showing that the combination of the personalised mRNA vaccine and Keytruda reduced the risk of melanoma returning or spreading compared with Keytruda alone.
The results are significant because this is the first randomised Phase 3 trial of a personalised neoantigen cancer vaccine to show a positive result.
The development could strengthen the case for using mRNA technology beyond infectious-disease vaccines.
Moderna’s shares rose more than 120% in early trading on August 19, with the stock gaining as much as 160% during the session, according to Reuters. Merck shares also climbed after the announcement.
How The Personalised Cancer Vaccine Works
Unlike traditional preventive vaccines, this experimental treatment is designed around the specific characteristics of an individual patient’s tumour.
The aim is to train the immune system to recognise cancer-specific mutations and attack cells carrying those targets.
The treatment is being studied as a personalised approach in combination with Keytruda, an established immunotherapy that helps the immune system fight cancer.
The Phase 3 trial focused on patients with high-risk melanoma after surgery.
The companies have not yet released the complete study data. Detailed information on overall survival, safety and other important measures will be needed to assess the treatment fully.
The companies plan to present further findings at an upcoming medical conference.
What The Moderna Trial Means For Investors
The strong rise in Moderna’s share price reflects investor expectations that a successful cancer treatment could open a major new business opportunity for the company, which has been looking to expand its portfolio beyond COVID-19 vaccines.
However, the stock movement does not mean the cancer vaccine is already approved or available to patients.
The treatment remains experimental, and further clinical data and regulatory steps are required before it could potentially reach the market.
Analysts have also cautioned that investors should wait for the full trial data before drawing firm conclusions about the treatment’s long-term effectiveness and commercial prospects.
Why The Cancer Vaccine News Matters
The development is being closely watched because mRNA technology is increasingly being explored for personalised cancer treatments.
A successful Phase 3 result could provide further evidence that the technology can be adapted to target cancer alongside existing therapies.
For Moderna, the result could also help reshape investor expectations around its future pipeline. The company and Merck are continuing to study the approach, including its potential application in other cancers.
